Liu Shufeng, Tang Xianhu, Li Xiaosheng, Cao Feng, Luo Juan, Zou Fangqin
Department of Nephrology, The First Affiliated Hospital of Gannan Medical University Ganzhou 341000, Jiangxi, China.
Am J Transl Res. 2021 Sep 15;13(9):10485-10492. eCollection 2021.
This study aimed to compare the efficacy of single hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD) combined with HD in the treatment of end-stage renal disease.
Seventy patients with end-stage renal disease in our hospital from January 2019 to December 2020 were included and divided into 35 patients in the single group (SG) and 35 patients in the combination group (CG) according to a random number table. The SG received HD treatment and the CG received CAPD combined with HD treatment.
Hemoglobin and serum albumin levels were higher, blood urea nitrogen (BUN) and serum creatinine (Scr) levels were lower, and interleukin-6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor-α (TNF-α) levels were lower in the CG than in SG at the end of treatment ( < 0.05). Ca levels were higher and P levels were decreased at the end of treatment in both groups compared with those before treatment ( < 0.05), and Ca and P levels at the end of treatment in the CG were not different from those in the SG ( > 0.05). The complication rate in the CG was 5.71%, which was lower than 25.71% in the SG ( < 0.05). Quality of life scores were higher in the CG than in the SG at the end of treatment ( < 0.05).
CAPD combined with HD can improve renal function and nutritional levels more significantly, control inflammatory responses more effectively, and reduce complications compared to single HD treatment in patients with end-stage renal disease.
本研究旨在比较单次血液透析（HD）与持续性非卧床腹膜透析（CAPD）联合HD治疗终末期肾病的疗效。
纳入我院2019年1月至2020年12月的70例终末期肾病患者，根据随机数字表分为单一组（SG）35例和联合组（CG）35例。SG接受HD治疗，CG接受CAPD联合HD治疗。
治疗结束时，CG组的血红蛋白和血清白蛋白水平较高，血尿素氮（BUN）和血清肌酐（Scr）水平较低，白细胞介素-6（IL-6）、C反应蛋白（CRP）和肿瘤坏死因子-α（TNF-α）水平也低于SG组（P<0.05）。与治疗前相比，两组治疗结束时血钙水平升高，血磷水平降低（P<0.05），且CG组治疗结束时的血钙和血磷水平与SG组无差异（P>0.05）。CG组的并发症发生率为5.71%，低于SG组的25.71%（P<0.05）。治疗结束时，CG组的生活质量评分高于SG组（P<0.05）。
与单次HD治疗相比，CAPD联合HD能更显著地改善终末期肾病患者的肾功能和营养水平，更有效地控制炎症反应，并减少并发症。
